company background image
PHAS

PhaseBio Pharmaceuticals NasdaqGM:PHAS Stock Report

Last Price

US$1.25

Market Cap

US$62.3m

7D

-6.7%

1Y

-60.2%

Updated

15 Aug, 2022

Data

Company Financials +
PHAS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PHAS Stock Overview

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases.

PhaseBio Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PhaseBio Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.25
52 Week HighUS$4.10
52 Week LowUS$0.50
Beta2.47
1 Month Change26.92%
3 Month Change38.11%
1 Year Change-60.19%
3 Year Change-83.29%
5 Year Changen/a
Change since IPO-75.00%

Recent News & Updates

Aug 12

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.

Shareholder Returns

PHASUS BiotechsUS Market
7D-6.7%1.4%3.6%
1Y-60.2%-19.6%-9.6%

Return vs Industry: PHAS underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: PHAS underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is PHAS's price volatile compared to industry and market?
PHAS volatility
PHAS Average Weekly Movement20.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PHAS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: PHAS's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200260Jonathan Mowhttps://phasebio.com

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.

PhaseBio Pharmaceuticals, Inc. Fundamentals Summary

How do PhaseBio Pharmaceuticals's earnings and revenue compare to its market cap?
PHAS fundamental statistics
Market CapUS$62.32m
Earnings (TTM)-US$102.84m
Revenue (TTM)US$818.00k

76.2x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHAS income statement (TTM)
RevenueUS$818.00k
Cost of RevenueUS$87.70m
Gross Profit-US$86.88m
Other ExpensesUS$15.96m
Earnings-US$102.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.06
Gross Margin-10,620.78%
Net Profit Margin-12,572.13%
Debt/Equity Ratio-3.5%

How did PHAS perform over the long term?

See historical performance and comparison